NEWS
Date
The University of Oklahoma Gallogly College of Engineering is deeply saddened to announce the passing of Dean Emeritus Thomas Landers, who served OU for 21 years, including 14 years as dean of the college, until his retirement in 2019.
Under his leadership, OU Engineering experienced a period of remarkable growth and transformation. Dean Landers oversaw the opening of the ExxonMobil Lawrence G. Rawl Engineering Practice Facility, Devon Energy Hall, and Gallogly Hall, as well as the establishment of the Stephenson School of Biomedical Engineering. These achievements helped expand opportunities for students and faculty while positioning the college for continued success.
“Dean Landers’ vision and leadership shaped the future of engineering at OU in profound ways,” said John Klier, current dean of the Gallogly College of Engineering. “Beyond the facilities and programs he helped bring to life, his greatest legacy is the community he fostered—his care for students, faculty, staff, and alumni continues to inspire us today.”
Dean Landers will be remembered not only for his accomplishments, but also for the meaningful relationships he built across the OU community.
Those wishing to honor his legacy may do so with a gift to the Tom L. Landers Memorial Scholarship, which supports future generations of OU Engineering students.
View obituary: https://www.schaudtfuneralservice.com/obituaries/thomas-landers
Beginning July 1, physicians from the University of Oklahoma College of Medicine Department of Emergency Medicine will provide medical direction to the Oklahoma Poison Center, a free, 24/7 helpline administered by the OU College of Pharmacy.
Pejman Kazempoor, an associate professor at the University of Oklahoma’s School of Aerospace and Mechanical Engineering, has been recognized for his commitment to addressing methane emissions and providing a cleaner world.
Muhammad Furqan, M.D., professor of hematology-oncology at the University of Oklahoma College of Medicine and Associate Director of Clinical Research at OU Health Stephenson Cancer Center, is leading a national clinical trial evaluating whether immunotherapy can improve outcomes for patients with stage I non-small cell lung cancer (NSCLC) following surgery.
